1. Home
  2. SHIM vs CNTB Comparison

SHIM vs CNTB Comparison

Compare SHIM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shimmick Corporation

SHIM

Shimmick Corporation

HOLD

Current Price

$4.48

Market Cap

149.2M

Sector

N/A

ML Signal

HOLD

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

HOLD

Current Price

$2.23

Market Cap

135.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHIM
CNTB
Founded
1990
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.2M
135.7M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
SHIM
CNTB
Price
$4.48
$2.23
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
58.9K
466.9K
Earning Date
05-14-2026
08-13-2026
Dividend Yield
N/A
N/A
EPS Growth
81.95
N/A
EPS
N/A
N/A
Revenue
$492,844,000.00
$64,000.00
Revenue This Year
$13.99
N/A
Revenue Next Year
$6.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.63
N/A
52 Week Low
$1.83
$1.23
52 Week High
$6.76
$3.82

Technical Indicators

Market Signals
Indicator
SHIM
CNTB
Relative Strength Index (RSI) 57.99 50.16
Support Level $3.44 $1.99
Resistance Level $4.47 $2.64
Average True Range (ATR) 0.24 0.12
MACD 0.06 -0.00
Stochastic Oscillator 79.22 54.02

Price Performance

Historical Comparison
SHIM
CNTB

About SHIM Shimmick Corporation

Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Share on Social Networks: